OSAKA, Japan-Thursday 12 May 2022 [ AETOS Wire ]
- Strong Performance Against FY2021 Management Guidance with Underlying Revenue Growth of +7.4% (Reported Revenue Growth +11.6%) and Strength Across Key Business Areas
- Highest Total Number of Approvals for Takeda in a Fiscal Year Across Japan (4 NMEs), China (3 NMEs), the U.S. (2 NMEs), and Europe (1 NME)
- Robust Free Cash Flow of JPY 943.7 Billion ($7.8B); Net Debt/Adjusted EBITDA of 2.8x
- FY2022 Outlook for Continued Topline and Core EPS Growth; Core Operating Profit Forecast to Reach JPY 1.1 Trillion and Reported Net Profit to Increase +26.9%
(BUSINESS WIRE) -- Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.
Takeda president and chief executive officer, Christophe Weber, commented: “We are pleased to report another year of strong performance, driven by our growth products. I am energized by the impact we are making for patients and by our continued momentum. We are seeing the potential of our innovative pipeline of approximately 40 clinical stage assets come to life, as demonstrated by the approval and launch of EXKIVITY® and LIVTENCITY™.
Looking ahead, our goal is to continue to grow Takeda into the most trusted, science-driven, digital biopharmaceutical company, and our strong performance against our strategy in FY2021 reinforces my confidence about the path we are on.”
Takeda chief financial officer, Costa Saroukos, commented: “Takeda’s strong FY2021 performance against our management guidance provides a solid foundation for our FY2022 outlook for continued topline growth and robust cash flow generation. This will allow us to allocate capital to maximize value for patients and shareholders as we invest in our R&D engine, new product launches and other growth drivers while continuing to rapidly reduce debt and return cash to shareholders.”
FINANCIAL AND BUSINESS HIGHLIGHTS
Results for FY2021 Ended March 31, 2022
(Billion yen, except | REPORTED | CORE(b) (Non-IFRS)(a) | UNDERLYING(c) (Non-IFRS)(a) | ||
FY2021 | vs. PRIOR YEAR | FY2021 | vs. PRIOR YEAR |
| |
Revenue | 3,569.0 | +11.6% | 3,420.5 | +7.0% | +7.4% |
Operating Profit | 460.8 | -9.5% | 955.2 | -1.3% | +5.4% |
Margin | 12.9% | -3.0pp | 27.9% | -2.3pp | 28.0% |
Net Profit | 230.1 | -38.8% | 663.7 | +1.3% |
|
EPS | 147 yen | -38.9% | 425 yen | +1.2% | +9.4% |
Operating Cash Flow | 1,123.1 | +11.1% |
| ||
Free Cash Flow | 943.7 | -23.8% |
| ||
(a) Further information regarding certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/financial-results/. |
No comments:
Post a Comment